PATENT CLAIM ANALYSIS

Application Number: 15990026
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "407000"]

Abstract:
The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT 2C  antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT 2C  inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R 1 , R 2 , R 3  and R 4  are independently hydrogen or C 1-6  alkyl etc.; R 5  is C 4-7  alkyl or —(CR 8 R 9 ) r -E; R 6 , R 7 , R 8  and R 9  are independently hydrogen, fluorine or C 1-6  alkyl; A is C 6-10  aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C 3-8  cycloalkyl or C 6-10  aryl etc.; L is oxygen, sulfur or —NR 10 —; n is 1, 2 or 3; R 10  is hydrogen or C 1-6  alkyl etc.; and X is hydrogen or halogen etc.

Claim (Index 31):
The method of  claim 30 , wherein the compound is 1-{1-(cyclopentylmethyl)-5-[(2,5-difluorobenzyl)oxy]-1H-pyrazol-3-yl}-N-methylmethanamine or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 93.0
- Lexical Diversity: 2.21795
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13810030', '14041246', '14324509', '15491130', '13503083']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8750491574646695
- 35 USC 102 Novelty (BERT): 0.6629136423370738
- Combined Prediction Score: 0.85383560595191
- Mean Citation Score: 665.109134
- Max Citation Score: 800.4784
- Similarity Product: 607.2269756067276

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test